A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).

Trial Details

NCT ID
NCT07300150
Phase
PHASE1
Sponsor
PAQ Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • PT0511
  • Cetuximab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • San Antonio, Texas, United States|29.42412,-98.49363
  • San Antonio, Texas, United States|29.42412,-98.49363
  • West Valley City, Utah, United States|40.69161,-112.00105
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Men or women \>=18 years of age
  • Histologically or cytologically confirmed advanced or metastatic solid malignancy.
  • Participant has a pathologically documented, locally advanced or metastatic malignancy with any KRAS mutation or wild-type (WT) KRAS amplification …
  • Participant must have received at least 1 and no more than 4 prior systemic therapies or be intolerant or ineligible for available therapies known …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →